• Zscaler recently appointed Nikhil Mehrotra, a marketing leader with over 18 years of experience and a background at Nutanix, as Senior Director of Marketing to support its expanding Zero Trust Everywhere platform.
• This leadership addition coincides with more than 700 enterprises broadening their use of Zscaler’s integrated zero trust architecture across users, cloud workloads, and branch locations, reinforcing the company’s focus on deepening platform adoption.
• We’ll now examine how Mehrotra’s marketing leadership, combined with rising Zero Trust Everywhere adoption, could influence Zscaler’s broader investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Zscaler Investment Narrative Recap

To be comfortable owning Zscaler, you need to believe its Zero Trust Everywhere platform can keep winning larger, stickier enterprise deployments despite intense security competition and ongoing losses. Mehrotra’s appointment supports Zscaler’s go to market execution but does not materially change the key near term catalyst, which is converting strong platform interest into improving cash flows, or the biggest risk, that larger cloud and security vendors bundle rival offerings and pressure Zscaler’s growth and margins.

The most relevant recent announcement here is Zscaler’s raised full year fiscal 2026 revenue guidance to about US$3.33 billion, which underscores how management is leaning into expansion as Zero Trust Everywhere adoption passes 700 enterprises. This higher top line target heightens the importance of effective marketing and sales execution while also magnifying the risk that elevated go to market and R&D spend, including new initiatives like AI security, could delay margin improvement if growth slows.

Yet beneath the growth story, investors should still be aware of how rising competition and bundled cloud security offerings could...

Zscaler's narrative projects $5.1 billion revenue and $131.1 million earnings by 2029. This requires 17.1% yearly revenue growth and a $208.5 million earnings increase from -$77.4 million today.

Uncover how Zscaler's forecasts yield a $192.58 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling Zscaler reaching about US$5.3 billion in revenue and turning earnings positive by 2029, which is far more aggressive than consensus. When you compare that outlook with concerns about high ongoing R&D and sales costs potentially delaying margin improvement, and then overlay fresh news like Mehrotra’s hire and rising Zero Trust Everywhere adoption, it is a reminder that your own view can legitimately differ from both camps and may evolve as new information arrives.

Explore 4 other fair value estimates on Zscaler - why the stock might be worth just $192.55!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zscaler research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Zscaler research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zscaler's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.